Allakos, Bay Area biotech firm based in San Carlos, is laying off 75% of its staff and eyeing a shutdown after its clinical ...

A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

A Bay Area biotech firm is laying off 75% of its staff following a flopped clinical trial. Allakos, based in San Carlos, ...

In terms of valuation, Allakos Inc’s market capitalization stands at $22.69 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value.

Citizens Jmp cut shares of Allakos (NASDAQ:ALLK – Free Report) from a strong-buy rating to a hold rating in a research note published on Monday,Zacks.com reports. Allakos Price Performance NASDAQ ALLK ...

Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and ...

Leerink Partners analyst Thomas Smith has reiterated their neutral stance on ALLK stock, giving a Hold rating on January 27.Invest with ...

Allakos halts AK006 development after phase 1 trial disappoints. Restructuring includes workforce cuts and $34 million-$38 ...

California, USA-based biotech Allakos saw its shares plummet 78.8% to $0.26 yesterday, after it announced disappointing ...

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Hold rating on Allakos (ALLK – Research Report), with a price ...

Following disappointing clinical trial results for AK006, Allakos will cut its workforce down to under 20 employees as it ...

Allakos said it plans to explore strategic alternatives, adding that it expects its cash, equivalents and investments will total $35 million to $40 million by the end of June. The company now sports a ...